Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Retension Pharmaceuticals Appoints Le Anne Bloedon As Evp of Clinical Development
PRIVATESep 10, 2026•about 2 hours ago
Position
Executive Vice President
Company
Retension Pharmaceuticals
LeAnne Bloedon
Falls ChurchBiotechnologyHealthcareHealth Care
Description
Retension Pharmaceuticals, Inc. announces the appointment of LeAnne Bloedon as Executive Vice President of Clinical Development and Operations. Additionally, Kevin Schutz will join as Vice President of Regulatory Affairs.
Company Information
Company
Retension Pharmaceuticals
Location
Falls Church, Virginia, United States
About
Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension. RTN-001 is a second generation PDE5i that preferentially distributes to cardiovascular tissues, where it acts to mediate a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension.
Don't miss Retension Pharmaceuticals's next move
Get an email the moment Retension Pharmaceuticals changes its leadership, hires an exec, or expands, usually minutes after it happens.
Falls ChurchBiotechnologyHealthcareHealth Care